NCT00706537View on ClinicalTrials.gov

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

November 30, 2008

Study Completion Date

November 30, 2008

Conditions
Non-Alcoholic Steatohepatitis(NASH)
Interventions
DRUG

Active treatment

20 mg CP-945598 as 15 and 5 mg tablet once daily for 3 weeks

DRUG

Placebo

Placebo as two tablets once daily for three weeks

Trial Locations (3)

27710

Pfizer Investigational Site, Durham

92801

Pfizer Investigational Site, Anaheim

92804

Pfizer Investigational Site, Anaheim

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY